
NNVC — NanoViricides Inc
NYSE MKT · Healthcare · Biotechnology
$1.21
-$0.04 (-3.20%)
NanoViricides Inc (NNVC) is a biotechnology company listed on NYSE MKT. It is led by Anil R. Diwan Ph.D., based in 1 Controls Drive, Shelton, CT, United States, 06484, with about 7 employees. NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Net income was -$1.8M. NNVC currently screens at market cap $22.2M.
Use this NNVC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NNVC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NNVC SEC filings page. Lician reads the product cache first so this HTML stays unique to NanoViricides Inc even when a live quote feed is slow.
About NanoViricides Inc
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
NNVC Key Statistics
Market Cap
$22.18M
Volume
75,483
Previous Close
$1.28
Day Range
$1.26 – $1.28
EPS
-$0.63
Revenue
$0.00
Net Income
-$9.47M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
7
NNVC Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$9.47M | -$8.29M | -$8.59M | -$8.11M |
| EPS (Diluted) | -$0.63 | -$0.70 | -$0.74 | -$0.70 |
Total Assets
$8.82M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$1.56M
Operating Cash Flow
-$8.48M
Free Cash Flow
$0.00
NanoViricides Inc Company Information
- Executive Chairman, President, CEO & Secretary
- Anil R. Diwan Ph.D.
- Headquarters
- 1 Controls Drive, Shelton, CT, United States, 06484
- Website
- www.nanoviricides.com
- Phone
- 203 937 6137
- IPO / Founded
- 2005-10-26
- Sector
- Healthcare
- Industry
- Biotechnology